Search alternatives:
teer decrease » greater decrease (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), use decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
teer decrease » greater decrease (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), use decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
2861
-
2862
The hourly temperatures in the phytotron.
Published 2025“…After 10 days of exposure to LTS, the pollen viability decreased most significantly at the heading stage by 44.67%, followed by the booting and the tillering stages. …”
-
2863
Fuchioka dataset 251021.
Published 2025“…Recent advances in 3D-MRI analysis have enabled quantitative cartilage thickness measurement. We hypothesized that OWHTO would result in measurable decreases in the PF joint cartilage thickness, predominantly medially and detectable using quantitative 3D-MRI. …”
-
2864
-
2865
(a to g) Administration of vitamin D3 increased serum phosphorus and triglycerides.
Published 2025“…Analyses of serum cholesterol, HDL and triglycerides also showed a non-significant decrease in the serum HDL level upon treatment with 125 µg/Kg vitamin D3, but a noticeable increase in the serum triglyceride level was observed with 125 µg/Kg of vitamin D3.…”
-
2866
Functional Delivery Systems for Targeting Tumor Heterogeneity: Reversing Immunosuppression and Modulating Cancer-Immune Interplay
Published 2025“…By developing a delivery vector that specifically targets circulating malignant cells (CMCs) in patient blood samples, we established an ex vivo platform to study the dynamic interplay between patient-derived cancer cells and immune cells. …”
-
2867
Functional Delivery Systems for Targeting Tumor Heterogeneity: Reversing Immunosuppression and Modulating Cancer-Immune Interplay
Published 2025“…By developing a delivery vector that specifically targets circulating malignant cells (CMCs) in patient blood samples, we established an ex vivo platform to study the dynamic interplay between patient-derived cancer cells and immune cells. …”
-
2868
Functional Delivery Systems for Targeting Tumor Heterogeneity: Reversing Immunosuppression and Modulating Cancer-Immune Interplay
Published 2025“…By developing a delivery vector that specifically targets circulating malignant cells (CMCs) in patient blood samples, we established an ex vivo platform to study the dynamic interplay between patient-derived cancer cells and immune cells. …”
-
2869
Functional Delivery Systems for Targeting Tumor Heterogeneity: Reversing Immunosuppression and Modulating Cancer-Immune Interplay
Published 2025“…By developing a delivery vector that specifically targets circulating malignant cells (CMCs) in patient blood samples, we established an ex vivo platform to study the dynamic interplay between patient-derived cancer cells and immune cells. …”
-
2870
Hydrate-Based Gas Storage Made Greener: Methane Hydrate Formation Enhancement with a Low-Toxicity Promoter
Published 2025“…Additionally, the effect of pressure variations (from 8 to 4 MPa at 288.2 K) was analyzed, revealing that a lower pressure decreases both the gas uptake and formation kinetics due to a reduced driving force. …”
-
2871
Hydrate-Based Gas Storage Made Greener: Methane Hydrate Formation Enhancement with a Low-Toxicity Promoter
Published 2025“…Additionally, the effect of pressure variations (from 8 to 4 MPa at 288.2 K) was analyzed, revealing that a lower pressure decreases both the gas uptake and formation kinetics due to a reduced driving force. …”
-
2872
Development and Use of a Galectin-1-Specific Nanobody for Tumor Imaging and Elucidating the Role of Galectin‑1 in Cancer
Published 2025“…Galectin-1 (GAL-1) plays a crucial role in cancer biology, especially in triple-negative breast cancer (TNBC), where it facilitates immune evasion and tumor progression. …”
-
2873
Hydrate-Based Gas Storage Made Greener: Methane Hydrate Formation Enhancement with a Low-Toxicity Promoter
Published 2025“…Additionally, the effect of pressure variations (from 8 to 4 MPa at 288.2 K) was analyzed, revealing that a lower pressure decreases both the gas uptake and formation kinetics due to a reduced driving force. …”
-
2874
Hydrate-Based Gas Storage Made Greener: Methane Hydrate Formation Enhancement with a Low-Toxicity Promoter
Published 2025“…Additionally, the effect of pressure variations (from 8 to 4 MPa at 288.2 K) was analyzed, revealing that a lower pressure decreases both the gas uptake and formation kinetics due to a reduced driving force. …”
-
2875
Hydrate-Based Gas Storage Made Greener: Methane Hydrate Formation Enhancement with a Low-Toxicity Promoter
Published 2025“…Additionally, the effect of pressure variations (from 8 to 4 MPa at 288.2 K) was analyzed, revealing that a lower pressure decreases both the gas uptake and formation kinetics due to a reduced driving force. …”
-
2876
Hydrate-Based Gas Storage Made Greener: Methane Hydrate Formation Enhancement with a Low-Toxicity Promoter
Published 2025“…Additionally, the effect of pressure variations (from 8 to 4 MPa at 288.2 K) was analyzed, revealing that a lower pressure decreases both the gas uptake and formation kinetics due to a reduced driving force. …”
-
2877
-
2878
Hydrate-Based Gas Storage Made Greener: Methane Hydrate Formation Enhancement with a Low-Toxicity Promoter
Published 2025“…Additionally, the effect of pressure variations (from 8 to 4 MPa at 288.2 K) was analyzed, revealing that a lower pressure decreases both the gas uptake and formation kinetics due to a reduced driving force. …”
-
2879
Hydrate-Based Gas Storage Made Greener: Methane Hydrate Formation Enhancement with a Low-Toxicity Promoter
Published 2025“…Additionally, the effect of pressure variations (from 8 to 4 MPa at 288.2 K) was analyzed, revealing that a lower pressure decreases both the gas uptake and formation kinetics due to a reduced driving force. …”
-
2880
Key safety measures including adverse events.
Published 2025“…<div><p>Background</p><p>The risk-to-benefit ratio of using combined oral contraceptive pills (COCPs) and/or metformin for comprehensive management of polycystic ovary syndrome (PCOS) in women with obesity is unclear. As there is a lack of robust evidence on the impact of these first-line medications on cardiovascular disease (CVD) risk, we compared the effect of COCPs, metformin or both on prevalence of metabolic syndrome (MetS) in participants with hyperandrogenic PCOS and hypothesized that COCPs would increase prevalence of MetS while metformin would decrease prevalence of MetS.…”